Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
NCT ID: NCT05992116
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
450 participants
OBSERVATIONAL
2023-09-01
2025-02-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iron Deficiency in Heart Failure Patients
NCT03883854
Impact of Iron Deficiency on Arrhythmic Events and Resting ECG Abnormalities in Patients Hospitalized With Heart Failure
NCT07277140
Changes in Myocardial Iron After Iron Administration
NCT03398681
Study of the Prevalence of Iron Deficiency in Patients With Heart Failure
NCT03924258
Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure
NCT03871699
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intravenous iron treatment has been shown to improve the quality of life, with an increased exercise capacity and a reduced risk for hospitalizations. The prevalence of iron deficiency in HFrEF and HFmrEF patients in Middle Eastern population has not been studied. We suspect a higher prevalence compared to Western populations especially in women.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* NYHA class II-IV.
* Able and willing to provide oral informed consent.
Exclusion Criteria
* Acute coronary syndrome.
* Known cases of iron overload (e.g. hemochromatosis); known cases of anemia due to other causes.
* Oral or intravenous iron supplements within the previous 3 months; erythropoietin stimulating agents or blood transfusion within the last 6 months.
* Active clinically relevant bleeding in the investigator's opinion.
* Patients with chronic inflammatory conditions (e.g. rheumatoid arthritis; Crohn's disease, etc.); active infection; and decompensated liver disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jordan Collaborating Cardiology Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ramzi Tabbalat
Role: STUDY_CHAIR
Abdali Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abdali Hospital
Amman, , Jordan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RT.IrnDefHFr.mr.EF.Jo001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.